• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

    10/2/23 7:00:00 AM ET
    $EBS
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email

    GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience.

    "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add valuable insight and experience as Emergent continues to partner with governments to prepare for public health threats and save lives."

    Mr. Fowler will serve on the Audit and Finance Committee, and Mr. DeGolyer will serve on the Compensation Committee.

    About Mr. Fowler:

    Currently, Mr. Fowler is the Chief Executive Officer of Pathalys Pharma, Inc., a biomedicines company focused on chronic kidney disease. He previously served as CEO of Liquidia Corporation (NASDAQ:LQDA), transforming the company from an early-stage research platform into a publicly traded biomedicines company. While at Liquidia, Mr. Fowler also co-founded and served as CEO of Envisia Therapeutics (acquired), an ophthalmology company focused on therapeutics. Prior to Liquidia, Mr. Fowler worked for seven years with Johnson and Johnson, serving as President of Centocor, Inc., a global multi-billion dollar subsidiary focused on biomedicines, and President of Ortho-McNeil Neurologics, a company focused on neurological disorders. He started his career with Eli Lilly and Company, working for thirteen years in a variety of sales, marketing and business development roles in both the pharmaceutical and medical device divisions. Mr. Fowler is the current chair of NCBIO and a past chair of the UNC Eshelman School of Pharmacy Foundation.

    Mr. Fowler earned his Bachelor of Science degree in Pharmacy and Master of Business Administration both from the University of North Carolina at Chapel Hill.

    About Mr. DeGolyer:

    With over 35 years of healthcare and corporate leadership experience, Mr. DeGolyer was most recently the Founder and Director of Vertice Pharma (a Warburg Pincus company), focused on specialty pharmaceuticals for U.S. institutional use, from 2015 until the company's sale in 2022. Prior to Vertice, he was Chief Operating Officer of Endo International, a Nasdaq-listed specialty pharmaceutical company, from 2013-2015. Between 2009 and 2013, he served on the Executive Committee of Sandoz AG (a Novartis company), one of the largest global generic companies, as CEO, Sandoz Inc., a $3.5bn generic pharmaceuticals and biosimilars company where he was responsible for leading over 3,000 associates in North America.

    Mr. DeGolyer started his career with Pfizer, Johnson & Johnson and Novartis in commercial roles of increasing responsibility. He previously served on the Board of HLS Therapeutics (commercial stage CV/CNS company) and TYME Technologies (development stage cancer company), both publicly traded companies, where he was also Chairman of the Compensation Committees. He also serves on several non-profit boards including Make-a-Wish-NJ and The Strong Women Foundation.

    Mr. DeGolyer received his Bachelor of Arts from the University of Rochester and earned a Master of Business Administration from Fairleigh Dickinson University.

    About Emergent BioSolutions

    At Emergent, our mission is to protect and enhance life. For 25 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, Twitter, and Instagram.

    Safe Harbor Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "should," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

    There are a number of important factors that could cause the company's actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements.

    Media:

    Matt Hartwig

    Senior Director, Media Relations

    240-760-0551

    [email protected]

    Investors:

    Richard Lindahl

    EVP and Chief Financial Officer

    240-631-3360

    [email protected]



    Primary Logo

    Get the next $EBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EBS
    $LQDA

    CompanyDatePrice TargetRatingAnalyst
    Emergent BioSolutions Inc.
    $EBS
    12/30/2024$15.00Buy
    H.C. Wainwright
    Liquidia Corporation
    $LQDA
    12/20/2024$20.00Overweight
    Wells Fargo
    Liquidia Corporation
    $LQDA
    10/16/2024Sector Outperform
    Scotiabank
    Emergent BioSolutions Inc.
    $EBS
    8/22/2024$16.00Buy
    Rodman & Renshaw
    Liquidia Corporation
    $LQDA
    8/19/2024Outperform → Strong Buy
    Raymond James
    Liquidia Corporation
    $LQDA
    8/16/2024$27.00Outperform
    Raymond James
    Liquidia Corporation
    $LQDA
    6/25/2024Perform
    Oppenheimer
    Emergent BioSolutions Inc.
    $EBS
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    More analyst ratings

    $EBS
    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will

      5/8/25 6:30:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Reports First Quarter 2025 Financial Results

      First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

      5/7/25 4:05:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

      MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company's Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-pre

      5/6/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    $LQDA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Liquidia Corporation

      10-Q - Liquidia Corp (0001819576) (Filer)

      5/8/25 7:00:23 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:40:47 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:05:36 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/16/24 4:05:20 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/4/24 5:51:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      12/18/23 5:02:01 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $EBS
    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $EBS
    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G filed by Emergent BioSolutions Inc.

      SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

      11/13/24 4:00:18 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

      SC 13G/A - Liquidia Corp (0001819576) (Subject)

      11/12/24 5:35:19 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

      SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

      11/8/24 5:23:28 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

      Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

      11/18/21 2:49:33 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

      H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

      12/30/24 7:24:57 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Liquidia Technologies with a new price target

      Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

      12/20/24 7:42:58 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Liquidia Technologies

      Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    $LQDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

      Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

      11/4/24 7:30:00 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

      Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg

      10/8/24 5:32:28 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Richard Ronald was granted 34,403 shares, increasing direct ownership by 48% to 105,517 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/2/25 8:31:43 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director White Marvin L was granted 34,403 shares, increasing direct ownership by 64% to 88,495 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/2/25 8:31:33 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fowler Neal Franklin was granted 34,403 shares, increasing direct ownership by 34% to 135,503 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/2/25 8:31:22 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    $LQDA
    Financials

    Live finance-specific insights

    See more
    • Emergent BioSolutions Reports First Quarter 2025 Financial Results

      First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

      5/7/25 4:05:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

      MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

      5/1/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

      GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be a

      4/22/25 8:00:00 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care